Last reviewed · How we verify

NCT02902835: BUPFAST

BUPrenorphine Facilitated Access and Supportive Treatment --AIM 3

Terminated NA Last updated 13 September 2018
What this trial tests

NA trial testing BUP_FAST in Opioid-related Disorders in 13 participants. Terminated before completion.

Timeline
1 September 2016
Primary endpoint
30 June 2018
30 June 2018

Quick facts

Lead sponsorMontefiore Medical Center
PhaseNA
StatusTerminated
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment13
Start date1 September 2016
Primary completion30 June 2018
Estimated completion30 June 2018
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Montefiore Medical Center

Who can join

18 and older, any sex, with Opioid-related Disorders. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this study is to test whether peer mentors (i.e., individuals with past opioid addiction and prior incarceration) can facilitate entrance into buprenorphine (Suboxone) treatment for individuals with opioid use disorder who were recently released from jail or prison. In order to test whether it is helpful to have peer mentors paired with recently released individuals, the investigators will conduct an 18 month study, recruiting 72 formerly incarcerated individuals and assigning them by chance selection (like flipping a coin) to either a group that will receive peer mentorship or a group that will receive a referral to a community clinic.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Montefiore Medical Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02902835.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing